Publicaciones en las que colabora con Manuel Crespo Hernández (18)

2022

  1. Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients

    Frontiers in Pharmacology, Vol. 13

  2. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

  3. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. Clinical characteristics, aetiology and mortality/recurrence risk factors of acute cholangitis in patients with and without biliary stent

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 9, pp. 445-450

  3. The benefits and safety of oral sequential antibiotic therapy in non-complicated and complicated Staphylococcus aureus bacteremia

    International Journal of Infectious Diseases, Vol. 102, pp. 554-560

2020

  1. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study

    AIDS Research and Therapy, Vol. 17, Núm. 1

  2. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

2019

  1. Moving beyond unsolicited consultation: Additional impact of a structured intervention on mortality in Staphylococcus aureus bacteraemia

    Journal of Antimicrobial Chemotherapy, Vol. 74, Núm. 4, pp. 1101-1107

  2. Short- versus long-course therapy in gram-negative bacilli bloodstream infections

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 38, Núm. 5, pp. 851-857

  3. Validation of a clinical decision tree to predict if a patient has a bacteraemia due to a β-lactamase producing organism

    Infectious Diseases, Vol. 51, Núm. 1, pp. 32-37

2018

  1. Clinical and microbiological characteristics of unusual manifestations of invasive pneumococcal disease

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 36, Núm. 5, pp. 284-289

  2. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae

    Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 11, pp. 3170-3175

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

  2. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792

2012

  1. Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 6, pp. 1462-1469

2001

  1. Mycotic pseudoaneurysm caused by Mycobacterium tuberculosis

    Anales de medicina interna (Madrid, Spain : 1984), Vol. 18, Núm. 11, pp. 594-596